In June 2025, the Indian Ministry of AYUSH introduced new guidelines to enhance the quality control of Ayurvedic products, emphasizing the need for standardized manufacturing processes and rigorous testing protocols. This policy change aims to bolster the credibility and marketability of Indian herbal medicaments on the global stage.
In September 2025, the WHO updated its guidelines on Good Manufacturing Practices (GMP) for herbal medicines, aligning them more closely with those for conventional pharmaceuticals. This revision underscores the importance of stringent quality assurance measures in the production of herbal products.
In December 2025, the EMA approved a new traditional herbal medicinal product under the simplified registration procedure, highlighting the EU's commitment to integrating traditional medicines into its healthcare system. This approval sets a precedent for future registrations of similar products.
In February 2026, the FDA issued a warning letter to a U.S. distributor of imported herbal supplements for non-compliance with labeling and marketing regulations, reinforcing the agency's strict oversight of herbal products in the market.
In March 2026, the Indian government announced a subsidy program to support small and medium-sized enterprises (SMEs) in the herbal medicine sector, aiming to enhance their production capabilities and export potential.
These developments reflect a dynamic regulatory environment and underscore the importance of compliance and quality assurance in the herbal medicament industry.
